These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 22920907)

  • 1. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.
    Soga S; Akinaga S; Shiotsu Y
    Curr Pharm Des; 2013; 19(3):366-76. PubMed ID: 22920907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsp90 molecular chaperone inhibitors: are we there yet?
    Neckers L; Workman P
    Clin Cancer Res; 2012 Jan; 18(1):64-76. PubMed ID: 22215907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSP90 inhibitors: current development and potential in cancer therapy.
    Sidera K; Patsavoudi E
    Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
    Miyata Y
    Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock protein 90 inhibitors as therapeutic agents.
    Gomez-Monterrey I; Sala M; Musella S; Campiglia P
    Recent Pat Anticancer Drug Discov; 2012 Sep; 7(3):313-36. PubMed ID: 22338602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
    Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
    Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014.
    Xiao Y; Liu Y
    Curr Drug Targets; 2020; 21(3):302-317. PubMed ID: 31465284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer.
    Haque A; Alam Q; Alam MZ; Azhar EI; Sait KH; Anfinan N; Mushtaq G; Kamal MA; Rasool M
    Curr Pharm Des; 2016; 22(20):2947-59. PubMed ID: 27013225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and development of purine-scaffold Hsp90 inhibitors.
    Chiosis G
    Curr Top Med Chem; 2006; 6(11):1183-91. PubMed ID: 16842155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.
    Alarcon SV; Mollapour M; Lee MJ; Tsutsumi S; Lee S; Kim YS; Prince T; Apolo AB; Giaccone G; Xu W; Neckers LM; Trepel JB
    Curr Mol Med; 2012 Nov; 12(9):1125-41. PubMed ID: 22804236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
    Garg G; Khandelwal A; Blagg BS
    Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P; Burrows F; Neckers L; Rosen N
    Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in Hsp90 inhibitors as antitumor agents.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Anticancer Agents Med Chem; 2008 Oct; 8(7):761-82. PubMed ID: 18855578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?
    Isaacs JS
    Expert Opin Investig Drugs; 2005 Jun; 14(6):569-89. PubMed ID: 16004589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
    Georgakis GV; Younes A
    Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
    Chiosis G; Caldas Lopes E; Solit D
    Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.
    Neckers L
    Curr Top Med Chem; 2006; 6(11):1163-71. PubMed ID: 16842153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat-shock protein 90: potential involvement in the pathogenesis of malignancy and pharmacological intervention.
    Ochel HJ; Gademann G
    Onkologie; 2002 Oct; 25(5):466-73. PubMed ID: 12415202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
    Dutta Gupta S; Bommaka MK; Banerjee A
    Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Old and New Approaches to Target the Hsp90 Chaperone.
    Sanchez J; Carter TR; Cohen MS; Blagg BSJ
    Curr Cancer Drug Targets; 2020; 20(4):253-270. PubMed ID: 31793427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.